Logo of Avecho Biotechnology (ASX:AVE)Latest Avecho Biotechnology (ASX:AVE) News

Page 1
Page 1 of 3

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Avecho restarts final Phase III insomnia trial cohort as licensing talks advance

Avecho has resumed recruitment for the final cohort of its pivotal Phase III insomnia trial after an interim review supported continuing at the original 519-participant target. The biotechnology company is also pursuing international licensing while holding $5.3 million in cash.
Ada Torres
28 Oct 2026

Healthcare Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Healthcare shares ended a difficult week with funding worries weighing on smaller companies, even as several groups reported stronger sales or clinical progress. Starpharma, Hydration Pharmaceuticals and Saluda were among the largest fallers, while Recce, Zoono and Genetic Signatures posted gains.
Logan Eniac
24 Oct 2026

Avecho gives ASX no explanation for 36% share price jump

Avecho Biotechnology has told the ASX it is unaware of any undisclosed information that could explain a sharp move in its share price and a significant increase in trading volume. The company also confirmed compliance with continuous disclosure rules after responding to an exchange price query.
Ada Torres
21 Oct 2026

Healthcare Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Healthcare shares delivered a mixed week as commercial wins and trial progress competed with fresh losses and capital needs.
Large moves in Alzheimer’s, fertility, diagnostics and medical devices gave investors clear milestones to track.
Logan Eniac
5 Sept 2026

Avecho Restarts Final Phase III Insomnia Trial Recruitment After Positive Interim Review

Avecho has resumed enrolment for the last stage of its pivotal Phase III trial of a TPM®-enhanced CBD capsule for insomnia, following a unanimous Data Monitoring Board recommendation to continue without expanding the sample size.
Ada Torres
31 Aug 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

Avecho Advances Phase III Insomnia Trial with Positive Interim Analysis and Simplified Capital Structure

Avecho Biotechnology has secured a unanimous recommendation to continue its Phase III insomnia trial without increasing sample size, alongside raising $1.9 million through option exercises and bolstering its cash position to $6.6 million.
Ada Torres
29 July 2026

Healthcare Wrap - Week 21 (18 May -> 22 May) 2026

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.
Logan Eniac
23 May 2026

Avecho Completes Treatment Phase in Phase III Insomnia Trial Ahead of June Interim Readout

Avecho Biotechnology has wrapped up the treatment phase for its pivotal Phase III insomnia trial involving 244 participants, setting the stage for an interim efficacy analysis expected in late June 2026.
Ada Torres
21 May 2026

Avecho Raises $1.9 Million From Option Exercises Ahead of Phase III Interim Results

Avecho Biotechnology has bolstered its cash reserves by $1.9 million through the exercise of listed options, positioning the company for a pivotal Phase III interim analysis readout for its insomnia treatment.
Ada Torres
12 May 2026

Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.
Logan Eniac
2 May 2026